Akt

Akt inhibitors target Akt, also called protein kinase B (PKB), a serine/threonine kinase in cell survival signaling. In 1995 the Akt proto-oncogene product was identified as a target of phosphatidylinositol 3-kinase (PI3K) activated by platelet-derived growth factor. Insulin and insulin-like growth factor 1 activate the kinase through phosphorylation at Thr308 and Ser473. The three isoforms, Akt1, Akt2 and Akt3, phosphorylate substrates that control metabolism, proliferation and apoptosis. The category includes the allosteric inhibitor MK-2206 2HCl, the catalytic-site inhibitor capivasertib and the alkylphospholipid perifosine. SC79, by contrast, promotes Akt phosphorylation and serves as an activator in pathway studies.

Items 76-100 of 218

  • HKB99
    Cat. No.
    A24208

    HKB99

    HKB99 is an allosteric inhibitor of phosphoglycerate mutase 1 (PGAM1) that induces apoptosis and suppresses cell migration by inhibiting the formation of invasive pseudopodia. It increases oxidative stress, activates the JNK/c-Jun pathway, and downregulates AKT and ERK signaling. HKB99 is a promising compound for the study of non-small cell lung cancer (NSCLC).

    5 mg
    $405.00
    10 mg
    $698.00
    All 4 sizes
  • PI3K/Akt/mTOR-IN-2
    Cat. No.
    A24214

    PI3K/Akt/mTOR-IN-2

    PI3K/Akt/mTOR-IN-2 is an inhibitor of the PI3K/AKT/mTOR signaling pathway with demonstrated anticancer activity. It selectively inhibits the proliferation of MDA-MB-231 cells with an IC50 of 2.29 μM and induces cell cycle arrest and apoptosis, making it a promising candidate for cancer research.

    5 mg
    $72.00
    10 mg
    $124.00
    All 4 sizes
  • Deferoxamine
    Cat. No.
    A24229

    Deferoxamine

    Synonyms: Deferoxamine B; Deferriferrioxamine B; Deferrioxamine

    Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.

    1 mg
    $45.00
    5 mg
    $125.00
    All 7 sizes
  • Larixol
    Cat. No.
    A24236

    Larixol

    Synonyms: (+)-Larixol

    Larixol is an fMLP inhibitor that also suppresses key signaling pathways involved in immune regulation, including Src kinase, ERK1/2, p38, and AKT phosphorylation. It disrupts the interaction between the βγ subunit of the fMLP receptor Gi protein and downstream effectors, thereby inhibiting fMLP-induced respiratory burst. Larixol effectively inhibits fMLP (0.1 μM)-induced superoxide anion production (IC50: 1.98 μM), cathepsin G release (IC50: 2.76 μM), and neutrophil chemotaxis. It mitigates neutrophil hyperactivation and helps reduce inflammation and tissue damage. Additionally, Larixol derivatives have shown inhibitory activity against TRPC6 functional mutants associated with focal segmental glomerulosclerosis (FSGS).

    1 mg
    $198.00
    5 mg
    $594.00
    All 4 sizes
  • 6-Demethoxytangeretin
    Cat. No.
    A24237

    6-Demethoxytangeretin

    6-Demethoxytangeretin is a flavonoid compound isolated from *Citrus reticulata* with demonstrated anti-inflammatory and anti-allergic properties. It inhibits IL-6 production and the expression of related genes in human mast cells by modulating the ALK and MAPK signaling pathways. Additionally, 6-Demethoxytangeretin enhances CRE-mediated transcription in hippocampal neurons, indicating potential neuroregulatory effects.

    5 mg
    $135.00
    10 mg
    $233.00
    All 4 sizes
  • Lipoteichoic acid
    Cat. No.
    A24481

    Lipoteichoic acid

    Lipoteichoic acid is an orally active compound with anti-inflammatory and antitumor properties. It is a key immune molecule found in Gram-positive bacteria that activates the complement system by upregulating C3 and inhibiting CD55. Lipoteichoic acid modulates macrophage autophagy via the PI3K/Akt/mTOR pathway, induces lung injury in mouse models, and inhibits melanin production.

    1 mg
    $162.00
    5 mg
    $486.00
    All 4 sizes
  • Veratramine
    Cat. No.
    A24634

    Veratramine

    Synonyms: NSC17821; NSC23880

    Veratramine is a selective inhibitor of the PI3K/Akt/mTOR signaling pathway and serves as a modulator of SIGMAR1. This compound facilitates autophagic apoptosis in tumor cells, effectively induces G0/G1 cell cycle arrest, and diminishes epithelial-mesenchymal transition (EMT) markers, thereby reducing tumor migration. Additionally, Veratramine exhibits neuroprotective effects by inhibiting SIGMAR1 interactions with NMDAR and the phosphorylation of NMDAR Ser896, resulting in reduced neurological damage in neuropathy models. Its diverse biological activities make it suitable for research on liver cancer, osteosarcoma, and diabetic peripheral neuropathy.

    5 mg
    $25.00
    10 mg
    $35.00
    All 7 sizes
  • PI3K/Akt/CREB activator 1
    Cat. No.
    A24641

    PI3K/Akt/CREB activator 1

    PI3K/Akt/CREB activator 1 is a potent, orally active compound that stimulates the PI3K/Akt/CREB signaling pathway. This activator promotes neuronal proliferation, induces differentiation of Neuro-2a cells into neuron-like cells, and facilitates the axon-dendrite polarization in primary hippocampal neurons by upregulating brain-derived neurotrophic factor. It is particularly relevant for research into vascular dementia (VaD).

    2 mg
    $80.00
    5 mg
    $100.00
    All 6 sizes
  • PI3K/AKT-IN-1
    Cat. No.
    A24642

    PI3K/AKT-IN-1

    PI3K/AKT-IN-1 is a potent dual inhibitor of the PI3K/AKT signaling pathway, exhibiting IC50 values of 6.99 μM for PI3Kγ, 4.01 μM for PI3Kδ, and 3.36 μM for AKT. This compound demonstrates significant anticancer activity by disrupting the PI3K/AKT axis, leading to the induction of caspase-3 dependent apoptosis. It serves as a valuable tool for research in cancer biology and therapeutic development targeting the PI3K/AKT pathway.

    1 mg
    $55.00
    5 mg
    $135.00
    All 8 sizes
  • MS21
    Cat. No.
    A24718

    MS21

    MS21 is a potent AKT PROTAC degrader designed to selectively target and degrade AKT proteins. This compound effectively inhibits mutations within the PI3K/PTEN pathway, leading to suppressed tumor cell proliferation and induction of cell cycle arrest. MS21 demonstrates significant anti-tumor activity, making it a valuable tool for cancer research and therapeutic development.

    5 mg
    $690.00
    10 mg
    $1,135.00
    All 5 sizes
  • MS170
    Cat. No.
    A24721

    MS170

    MS170 is a highly selective PROTAC degrader targeting the AKT isoforms. With a DC50 value of 32 nM, MS170 effectively depletes total AKT (T-AKT) in cellular assays. It demonstrates strong binding affinity for AKT1, AKT2, and AKT3, with dissociation constants (Kd) of 1.3 nM, 77 nM, and 6.5 nM, respectively. This compound is suitable for research applications investigating AKT-related signaling pathways and therapeutic interventions in cancer biology.

    1 mg
    $320.00
    5 mg
    $985.00
    All 3 sizes
  • Ergothioneine
    Cat. No.
    A24788

    Ergothioneine

    Synonyms: L-(+)-Ergothioneine

    Ergothioneine is an endogenous metabolite that acts as a potent antioxidant. It functions primarily as a specific inhibitor of p38 MAPK and Akt, which are critical signaling pathways involved in cellular stress responses. Ergothioneine is utilized in research focused on neuroprotection, cell apoptosis, and oxidative stress, making it a valuable compound for investigations into cellular resilience and health.

    2 mg
    $25.00
    5 mg
    $40.00
    All 7 sizes
  • Atranorin
    Cat. No.
    A24806

    Atranorin

    Atranorin is a secondary metabolite derived from lichens that acts as an AKT inhibitor. This compound demonstrates a wide range of biological activities, including antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Notably, Atranorin has IC50 values of 117 μM for scavenging DPPH free radicals and less than 10 μM for ABTS radicals, highlighting its potent antioxidant capacity. Additionally, Atranorin promotes wound healing and can be utilized in research focused on myelodysplastic syndromes, tumors, and various inflammatory conditions.

    1 mg
    $70.00
    5 mg
    $170.00
    All 3 sizes
  • Methyl Eugenol
    Cat. No.
    A24888

    Methyl Eugenol

    Synonyms: O-methyleugenol; eugenyl methyl ether; Eugenol Methyl ether; 4-allylveratrole

    Methyl Eugenol is an anti-insect agent primarily effective against the oriental fruit fly (Bactrocera dorsalis). In addition to its insecticidal properties, Methyl Eugenol exhibits anti-cancer and anti-inflammatory activities, making it a versatile compound for biological research. It has been shown to induce autophagy in cells and can be utilized in studies related to intestinal ischemia/reperfusion injury.

    50 mg
    $25.00
    100 mg
    $30.00
    All 8 sizes
  • PP2A Cancerous-IN-1
    Cat. No.
    A25010

    PP2A Cancerous-IN-1

    PP2A Cancerous-IN-1 is a strong and potent CIP2A (Cancerous inhibitor of PP2A) and p-Akt inhibitor. PP2A Cancerous-IN-1 shows the most potent antiproliferative activities. PP2A Cancerous-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • AKT-IN-14 free base
    Cat. No.
    A25011

    AKT-IN-14 free base

    AKT-IN-14 free base is a highly potent inhibitor of the AKT family of serine/threonine kinases, demonstrating IC50 values of less than 0.01 nM, 1.06 nM, and 0.66 nM for AKT1, AKT2, and AKT3, respectively. This compound is valuable for research applications focused on cancer biology, particularly in studies investigating the role of AKT signaling in tumor progression and therapeutic resistance.

    Out of stock

    All 3 sizes
  • AKT-IN-28
    Cat. No.
    A25196

    AKT-IN-28

    AKT-IN-28 is an allosteric inhibitor of Akt, a key protein involved in cell survival and metabolism. It exhibits a binding affinity with a Kd of 2.07 μM and demonstrates the ability to significantly inhibit Akt activity. This compound induces apoptosis, arrests the cell cycle in the G2/M phase, and suppresses proliferation, migration, and metabolic processes in KRAS mutant colorectal cancer cells, making it a valuable tool for cancer research applications focused on targeting the Akt pathway.

    Out of stock

    All 3 sizes
  • Akt1/Akt2-IN-2
    Cat. No.
    A25390

    Akt1/Akt2-IN-2

    Akt1/Akt2-IN-2 is an allosteric dual inhibitor targeting Akt1 and Akt2, exhibiting IC50 values of 138 nM and 212 nM, respectively. This compound enhances caspase-3 activity and effectively reduces the viability of various tumor cell lines. Its application in cancer research highlights its potential for investigating therapeutic strategies that disrupt Akt-mediated signaling pathways.

    5 mg
    $130.00
    25 mg
    $1,275.00
    All 4 sizes
  • AKTide-2T
    Cat. No.
    A25595

    AKTide-2T

    AKTide-2T is a selective substrate for AKT, demonstrating competitive inhibition of histone H2B phosphorylation with a Ki of 12 nM. This peptide mimics the optimal phosphorylation sequence of Akt, effectively serving as an inhibitory agent due to the absence of Thr at the S22 position in the wildtype sequence. It is a valuable tool for studying AKT signaling pathways and their implications in various biological processes.

    1 mg
    $235.00
    All 1 sizes
  • DETD-35
    Cat. No.
    A25608

    DETD-35

    DETD-35 is a potent inhibitor of the Akt signaling pathway, with additional effects on MEK-ERK and STAT3 pathways. It induces apoptosis in cancer cells and decreases their resistance to Vemurafenib. DETD-35 demonstrates effective inhibitory activity against various melanoma cell lines, with IC50 values of 2.5 to 6.0 μM across wild-type and mutant strains. This compound is a valuable tool for investigating mechanisms of anti-melanoma therapies.

    Out of stock

    All 3 sizes
  • AKT-IN-26
    Cat. No.
    A25612

    AKT-IN-26

    AKT-IN-26 (Compound 453) is an AKT inhibitor that binds to the Pleckstrin homology (PH) domain of AKT. AKT-IN-26 can be used in research related to AKT pathway-associated cell proliferation and cancer.

    25 mg
    $250.00
    50 mg
    $365.00
    All 4 sizes
  • Isocucurbitacin B
    Cat. No.
    A25613

    Isocucurbitacin B

    Isocucurbitacin B selectively inhibits the PI3K/AKT signaling pathways, along with the MAPK and STAT3 pathways, demonstrating notable anti-cancer properties. This natural terpenoid, derived from Pedicellus melo, effectively suppresses cancer cell proliferation, migration, and invasion. Additionally, Isocucurbitacin B induces apoptosis and facilitates G2/M phase cell cycle arrest, while altering intracellular cholesterol and pH levels, and elevating intracellular calcium levels. It serves as a valuable reagent for research applications in cancer biology, particularly in the study of glioma.

    1 mg
    $205.00
    2 mg
    $305.00
    All 6 sizes
  • AM-9635
    Cat. No.
    A25616

    AM-9635

    AM-9635 is a selective Akt inhibitor that targets the PI3Kδ pathway. It demonstrates significant in vitro and in vivo efficacy, effectively inhibiting PI3Kδ-dependent B cell receptor-mediated AKT phosphorylation. This compound has been shown to suppress the production of specific IgG and IgM antibodies in a rat model immunized with Aplysia leocyanin (KLH), making it useful for research applications in immunology and cancer biology.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • CCT129254
    Cat. No.
    A25617

    CCT129254

    Synonyms: AT 11854

    CCT129254 is a selective inhibitor of the Akt pathway, targeting the serine/threonine kinase Akt. This compound demonstrates significant reduction in melanoma cell motility in vivo, highlighting its potential utility in cancer research. CCT129254 may serve as a valuable tool for studying the role of Akt in tumor progression and therapeutic resistance.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • HS-345
    Cat. No.
    A25624

    HS-345

    HS-345 is a selective inhibitor of the TrkA/Akt signaling pathway, demonstrating significant anti-cancer effects in pancreatic cancer models. It inhibits the growth and proliferation of pancreatic cancer cells while inducing apoptosis. Moreover, HS-345 disrupts angiogenesis by downregulating the expression of HIF-1α and VEGF. This compound shows potential as a valuable tool for research into pancreatic cancer therapies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes

Items 76-100 of 218

Added to your cart

View Cart Checkout

    Loading...